Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 967 | 44% |
| 2020 | 11 | 1,020 | 46% |
| 2021 | 7 | 1,041 | 49% |
| 2022 | 10 | 988 | 51% |
| 2023 | 10 | 1,153 | 53% |
| 2024 | 11 | 1,180 | 54% |
| 2025 from claims | – | 1,184 1,086–1,252 | 55% |
| 2026 forecast | – | 1,243 1,094–1,435 | 55% |
| 2027 forecast | – | 1,301 1,112–1,550 | 56% |
| 2028 forecast | – | 1,360 1,135–1,666 | 56% |
| 2029 forecast | – | 1,423 1,162–1,784 | 57% |
| 2030 forecast | – | 1,488 1,192–1,906 | 57% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 96% of the cases CMS names in Arizona; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 77% inpatient hospital, 4% hospital outpatient, 5% surgery center, 13% office. The share outside the hospital has moved +13 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 42 | 4,550+3.4%/yr | +3.4%/yr | 1.4 | 29% | 6,830 in 2030+7%/yr |
| Colorado | 4 | 635+0.4%/yr | +0.4%/yr | 1.3 | 18% | 790 in 2030+3.6%/yr |
| Washington | 3 | 587+1.3%/yr | +1.3%/yr | 0.8 | 0% | 1,070 in 2030+11%/yr |
| Nevada | 3 | 412−4.7%/yr | −4.7%/yr | 1.4 | 0% | 540 in 2030+4.7%/yr |
| Oregon | 2 | 343+2.3%/yr | +2.3%/yr | 0.8 | 0% | 370 in 2030+1.1%/yr |
| Idaho | 2 | 265+6.5%/yr | +6.5%/yr | 1.3 | 0% | 360 in 2030+5.1%/yr |
| Utah | 0 | 253+3.2%/yr | +3.2%/yr | 1.2 | 0% | 480 in 2030+11%/yr |
| New Mexico | 1 | 215+4.7%/yr | +4.7%/yr | 0.9 | 0% | 60 in 2030−18%/yr |
| Montana | 2 | 147+16%/yr | +16%/yr | 0.8 | 0% | 150 in 2030+0.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.02.6× | 100% | 10,200 in 2030+0.2%/yr |
| Peripheral arterial intervention | 38 | 4,850−6.8%/yr | −6.8%/yr | 6.21.3× | 74% | 4,560 in 2030−1%/yr |
| Dialysis access | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.21.1× | 88% | 4,140 in 2030+2%/yr |
| Carotid revascularization | 21 | 884−3%/yr | −3%/yr | 1.21.5× | 0% | 1,070 in 2030+3.3%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 322−6.9%/yr | −6.9%/yr | 0.41.4× | 0% | 370 in 2030+2.5%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Penumbra leads with 43% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 14 companies reported engagement with Arizona’s surgeons worth $243K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.